 |
VaxInnate
Last updated: April 19, 2024
Wayne Pisano, President and CEO, and Lynda Tussey, chief scientific officer
Country: USA | Funding: $132.5M (+)
Website: http://vaxinnate.com/
VaxInnate, a privately-held biotechnology company located in Cranbury, NJ, is pioneering breakthrough technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system. Using this technology, vaccines can be produced by low-cost, highly scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture vaccine production.
Website: http://vaxinnate.com/
VaxInnate, a privately-held biotechnology company located in Cranbury, NJ, is pioneering breakthrough technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, a potent stimulator of the innate immune system. Using this technology, vaccines can be produced by low-cost, highly scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture vaccine production.
